早期阴茎假体植入耐火性缺血性 priapism:一个叙事审查
Ross Calopedos1, Davide Trubbia2, David Ralph2,3
1East Sydney Private Hospital, Sydney, Australia.
International journal of impotence research
|November 5, 2025
概括
建议在耐火性缺血性 priapism (RIP) 时早期植入阴茎假体,以防止永久性勃起功能障碍. 这种方法提供了更好的患者满意度和比延迟手术更少的并发症.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 安德罗学与人类学
- 手术创新 在外科创新.
背景情况:
- 缺血性 priapism (IP) 是一种危急的疾病,可能导致不可逆转的勃起功能障碍 (ED) 和阴茎形.
- 耐火性缺血性 priapism (RIP),持续超过48小时尽管治疗,需要先进的管理策略.
- 对RIP的延迟干预可能会导致严重的身体损伤,包括光滑肌肉缩和纤维化,阻碍自然勃起恢复.
研究的目的:
- 审查和评估早期阴茎假体 (PP) 植入用于管理耐火性缺血性青症 (RIP) 的疗效.
- 为了比较RIP患者早期与延迟PP插入的结果.
- 探索RIP管理的病理生理学方面,诊断工具和外科考虑.
主要方法:
- 对早期阴茎假体 (PP) 插入用于耐火性缺血性priapism (RIP) 的现有证据的系统审查.
- 分析IP的病理生理进展,包括身体光滑肌肉死亡和纤维化.
- 早期与延迟PP植入结果的比较评估,考虑患者满意度,修订率,阴茎长度和并发症.
主要成果:
- 与延迟程序相比,早期PP植入显示出更高的患者满意度.
- 接受早期PP插入的患者经历了更低的修订率和更少的阴茎缩短.
- 较少的术后并发症与RIP早期阴茎假体植入有关.
结论:
- 早期的阴茎假体植入被支持作为耐火性缺血性青症 (RIP) 的首选管理策略.
- 这种积极的手术方法可以保护阴茎的功能,并最大限度地减少长期并发症.
- 需要进一步的研究来优化外科手术方案,并提高患者在RIP管理中的结果.
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
450
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
450
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
547
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
547